Kairos Pharma, LTD. — Director's Dealing 2025

Dec 30, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2025-10-08

Reporting Person: Bhowmick Neil (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-08	COMMON STOCK	A	171756	$0.00	Acquired	1311739	Direct

Footnotes

F1: Represents 171,756 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 171,756 RSUs are scheduled to vest on the on the first anniversary of the grant date which is October 8, 2026.

F2: Consists of (1) 1,135,317 shares of common stock and (2) 176,422 RSUs which remain subject to vesting.